December 1, 2010 | Life science companies are irked by the FDA's lengthy drug review process, increasing fees, and issues raised late in the process according to a PricewaterhouseCoopers survey released yesterday. Despite some improvements since the 1997 FDA Modernization Act, drug companies--especially small ones--are still frustrated. San Diego Union Tribune